Yttrium-90 Radioembolization After Local Hepatic Therapy: How Prior Treatments Impact Patient Selection, Dosing, and Toxicity

Tech Vasc Interv Radiol. 2019 Jun;22(2):112-116. doi: 10.1053/j.tvir.2019.02.012. Epub 2019 Feb 28.

Abstract

Numerous local treatment strategies now exist for patients with primary and metastatic liver tumors. Increasingly, patients who cannot be adequately treated with a single form of focal therapy, go on to receive a variety of sequential treatments. However, the impact of each prior therapy on subsequent treatments and the cumulative toxicity of these therapies remains uncertain. Yttrium-90 radioembolization is becoming an increasingly common treatment for patients with hepatic malignancies. Though the baseline toxicity of radioembolization is low, greater care must be taken when treating patients who have undergone prior hepatic treatments. While this population can be treated safely, additional measures should be taken to ensure that patients are carefully screened and all effort is made to minimize liver toxicity.

Keywords: Radioembolization; Yttrium-90; liver toxicity.

Publication types

  • Review

MeSH terms

  • Embolization, Therapeutic / adverse effects
  • Embolization, Therapeutic / methods*
  • Humans
  • Liver Neoplasms / diagnostic imaging
  • Liver Neoplasms / radiotherapy
  • Liver Neoplasms / therapy*
  • Organs at Risk
  • Patient Selection*
  • Radiation Injuries / prevention & control*
  • Radiography, Interventional*
  • Radiotherapy Dosage
  • Risk Factors
  • Yttrium Radioisotopes / adverse effects
  • Yttrium Radioisotopes / therapeutic use*

Substances

  • Yttrium Radioisotopes
  • Yttrium-90